GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cordlife Group Ltd (SGX:P8A) » Definitions » EV-to-EBITDA

Cordlife Group (SGX:P8A) EV-to-EBITDA : -2.99 (As of Jun. 07, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cordlife Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cordlife Group's enterprise value is S$-25.62 Mil. Cordlife Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$8.56 Mil. Therefore, Cordlife Group's EV-to-EBITDA for today is -2.99.

The historical rank and industry rank for Cordlife Group's EV-to-EBITDA or its related term are showing as below:

SGX:P8A' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.56   Med: 9   Max: 62.19
Current: -2.99

During the past 12 years, the highest EV-to-EBITDA of Cordlife Group was 62.19. The lowest was -3.56. And the median was 9.00.

SGX:P8A's EV-to-EBITDA is ranked better than
99.07% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.22 vs SGX:P8A: -2.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Cordlife Group's stock price is S$0.14. Cordlife Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.014. Therefore, Cordlife Group's PE Ratio for today is 10.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Cordlife Group EV-to-EBITDA Historical Data

The historical data trend for Cordlife Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cordlife Group EV-to-EBITDA Chart

Cordlife Group Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.89 3.86 3.78 2.06 2.28

Cordlife Group Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 - 2.06 - 2.28

Competitive Comparison of Cordlife Group's EV-to-EBITDA

For the Diagnostics & Research subindustry, Cordlife Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cordlife Group's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cordlife Group's EV-to-EBITDA falls into.



Cordlife Group EV-to-EBITDA Calculation

Cordlife Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-25.621/8.556
=-2.99

Cordlife Group's current Enterprise Value is S$-25.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cordlife Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$8.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cordlife Group  (SGX:P8A) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cordlife Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.14/0.014
=10.00

Cordlife Group's share price for today is S$0.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cordlife Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Cordlife Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cordlife Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cordlife Group (SGX:P8A) Business Description

Traded in Other Exchanges
Address
1 Yishun Industrial Street 1, Number 06-01/09, A'Posh Bizhub, Singapore, SGP, 768160
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Cordlife has processing and storage facilities in six key markets across Asia, namely Singapore, Hong Kong, Malaysia, India, Indonesia, and the Philippines. The company has two segments - The Banking segment, comprises cord blood, cord lining, and cord tissue services. The Diagnostics segment comprises Metascreen, which is a non-invasive metabolic screening test specially designed for newborn babies, non-invasive prenatal testing service and Eyescreen, a paediatric eye-screening service.

Cordlife Group (SGX:P8A) Headlines

No Headlines